Shmuel Cabilly

About

Portfolio · 4

DiA Imaging Analysis

AI-driven Ultrasound Analysis

1 round $14.0M committed Latest: 2021-08

Raziel Therapeutics

Injectable Drug for Treatment of Obesity

1 round $22.0M committed Latest: 2019-12

Treato

Analysis of Prescription Drug Reviews

2 rounds $20.0M committed Latest: 2013-04

Medasense Biometrics

Noninvasive Pain-monitoring Solutions

Led ★ 1 round $1.0M committed Latest: 2008-07

Investment activity

1 portfolio exit on record.

Q&A

What is Shmuel Cabilly's primary investment focus?

Shmuel Cabilly primarily focuses on the Health Tech & Life Sciences sector, with all four of his listed portfolio companies operating in this area.

Has Shmuel Cabilly had any notable exits recently?

Yes, Shmuel Cabilly saw an exit in May 2023 when DiA Imaging Analysis, an AI-driven ultrasound analysis company, was acquired by Philips for $100M.

What are some of Shmuel Cabilly's key portfolio companies?

Shmuel Cabilly's portfolio includes Medasense Biometrics, which develops noninvasive pain-monitoring solutions.

What is Shmuel Cabilly's background before becoming an angel investor?

Shmuel Cabilly is a scientist who co-founded Ethrog Biotechnology, where he invented two dry-buffer technologies. He also developed a new technology for recombinant antibody production at the City of Hope Research Institute, which is the basis for 20 drugs on the market today.

In which funding stages does Shmuel Cabilly typically invest?

Shmuel Cabilly has invested across various stages, including Pre-Seed, Seed, A Round, B Round, C Round, D Round, E Round, F Round, and G Round.

When did Shmuel Cabilly make his most recent recorded investment?

Shmuel Cabilly's most recent recorded investment round occurred in August 2021.

What is Shmuel Cabilly's current involvement with portfolio companies?

Shmuel Cabilly currently holds board and advisor roles, including Board Member at Irody, Board Observer at Medasense, and Board Member at Pango.